Share on StockTwits

Alimera Sciences (NASDAQ:ALIM) SVP David Holland unloaded 5,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $5.64, for a total value of $28,200.00. Following the completion of the transaction, the senior vice president now directly owns 100,862 shares of the company’s stock, valued at approximately $568,862. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Alimera Sciences (NASDAQ:ALIM) traded down 0.93% during mid-day trading on Monday, hitting $5.32. 136,950 shares of the company’s stock traded hands. Alimera Sciences has a 52 week low of $1.65 and a 52 week high of $8.44. The stock’s 50-day moving average is $5.89 and its 200-day moving average is $6.22. The company’s market cap is $214.5 million.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.05. The company had revenue of $2.08 million for the quarter, compared to the consensus estimate of $1.15 million. During the same quarter last year, the company posted ($0.27) earnings per share. Analysts expect that Alimera Sciences will post $-1.19 EPS for the current fiscal year.

Alimera Sciences, Inc is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.